Literature DB >> 22487066

Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons.

Waleed M Mohammad1, Guillaume Martel, Richard Mimeault, Robert J Fairfull-Smith, Rebecca C Auer, Fady K Balaa.   

Abstract

BACKGROUND: The resectability of colorectal liver metastases is in part largely based on the surgeon's assessment of cross-sectional imaging. This process, while guided by principles, is subjective. The objective of the present study was to assess agreement between hepatic surgeons regarding the resectability of colorectal liver metastases.
METHODS: Forty-six hepatic surgeons across Canada were invited. A patient with biologically favourable disease was presented after having received neoadjuvant chemotherapy. The scenario was matched with 10 different scrollable abdominal CT scans representing a maximum response after six cycles of chemotherapy. Surgeons were asked to offer an opinion on resectability of liver metastases, and whether they would use adjunct modalities to hepatic resection.
RESULTS: Twenty-six surgeons participated. Twenty responses were complete. The median number of scenarios deemed resectable was 6/10 (range 3-8). Two control scenarios demonstrated perfect agreement. Agreement on resectability was poor for 4/8 test scenarios, of which one scenario demonstrated complete disagreement. Among resectable cases, the pattern of use of adjunct modalities was variable. A median ratio of 0.87 adjunct modality per resectable scenario per surgeon was used (range 0.25-1.75).
CONCLUSION: A significant lack of agreement was identified among surgeons on the resectability and use of adjunct modalities in the treatment of colorectal liver metastases.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22487066      PMCID: PMC3384848          DOI: 10.1111/j.1477-2574.2012.00440.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  27 in total

1.  Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization.

Authors:  Ihab R Kamel; Michael A Choti; Karen M Horton; H J V Braga; Bernard A Birnbaum; Elliot K Fishman; Richard E Thompson; David A Bluemke
Journal:  Radiology       Date:  2003-06       Impact factor: 11.105

Review 2.  Measuring processes of care in general surgery: assessment of technical and nontechnical skills.

Authors:  Pierre-Anthony E Leake; David R Urbach
Journal:  Surg Innov       Date:  2010-08-25       Impact factor: 2.058

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive.

Authors:  P Rougier; C Milan; F Lazorthes; G Fourtanier; C Partensky; H Baumel; J Faivre
Journal:  Br J Surg       Date:  1995-10       Impact factor: 6.939

5.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

6.  Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Authors:  René Adam; Valérie Delvart; Gérard Pascal; Adrian Valeanu; Denis Castaing; Daniel Azoulay; Sylvie Giacchetti; Bernard Paule; Francis Kunstlinger; Odile Ghémard; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

Review 7.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

8.  Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

Authors:  C Pozzo; M Basso; A Cassano; M Quirino; G Schinzari; N Trigila; M Vellone; F Giuliante; G Nuzzo; C Barone
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

9.  Determinants of survival in liver resection for colorectal secondaries.

Authors:  H Ekberg; K G Tranberg; R Andersson; C Lundstedt; I Hägerstrand; J Ranstam; S Bengmark
Journal:  Br J Surg       Date:  1986-09       Impact factor: 6.939

10.  Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Authors:  Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  13 in total

1.  Resectability of colorectal liver metastases: an evolving definition.

Authors:  Flavio G Rocha; W Scott Helton
Journal:  HPB (Oxford)       Date:  2012-03-19       Impact factor: 3.647

Review 2.  Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases.

Authors:  Fernando A Alvarez; Rodrigo Sanchez Claria; Sebastian Oggero; Eduardo de Santibañes
Journal:  World J Gastrointest Surg       Date:  2016-06-27

Review 3.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

Review 4.  [Why are too few patients with colorectal liver metastases submitted to resection?]

Authors:  G A Stavrou; O Ghamarnejad; Karl J Oldhafer
Journal:  Chirurg       Date:  2021-02-18       Impact factor: 0.955

5.  Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?

Authors:  Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball
Journal:  Can J Surg       Date:  2018-08       Impact factor: 2.089

Review 6.  A systematic review of repeat hepatectomy for recurrent colorectal liver metastases.

Authors:  Vincent W T Lam; Tony Pang; Jerome M Laurence; Emma Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson
Journal:  J Gastrointest Surg       Date:  2013-03-23       Impact factor: 3.452

Review 7.  A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases.

Authors:  Vincent W T Lam; Jerome M Laurence; Emma Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson
Journal:  HPB (Oxford)       Date:  2012-11-07       Impact factor: 3.647

Review 8.  Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.

Authors:  Emily Khoo; Stephen O'Neill; Ewan Brown; Stephen J Wigmore; Ewen M Harrison
Journal:  HPB (Oxford)       Date:  2016-04-20       Impact factor: 3.647

9.  Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?

Authors:  Jean-Michel Aubin; Alexsander K Bressan; Sean C Grondin; Elijah Dixon; Anthony R MacLean; Sean Gregg; Patricia Tang; Gilaad G Kaplan; Guillaume Martel; Chad G Ball
Journal:  Can J Surg       Date:  2018-06-01       Impact factor: 2.089

10.  ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) does not affect proliferation, apoptosis, or angiogenesis as compared to standard liver resection for colorectal liver metastases.

Authors:  Katharina Joechle; Christian Moser; Petra Ruemmele; Katharina M Schmidt; Jens M Werner; Edward K Geissler; Hans J Schlitt; Sven A Lang
Journal:  World J Surg Oncol       Date:  2017-03-07       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.